149 related articles for article (PubMed ID: 22880112)
1. Treatment-related death in patients with small-cell lung cancer in phase III trials over the last two decades.
Ochi N; Hotta K; Takigawa N; Oze I; Fujiwara Y; Ichihara E; Hisamoto A; Tabata M; Tanimoto M; Kiura K
PLoS One; 2012; 7(8):e42798. PubMed ID: 22880112
[TBL] [Abstract][Full Text] [Related]
2. Time trend in treatment-related deaths of patients with advanced non-small-cell lung cancer enrolled into phase III trials of systemic treatment.
Fujiwara Y; Hotta K; Di Maio M; Kiura K; Takigawa N; Tabata M; Tanimoto M
Ann Oncol; 2011 Feb; 22(2):376-82. PubMed ID: 20699278
[TBL] [Abstract][Full Text] [Related]
3. Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results.
Oze I; Hotta K; Kiura K; Ochi N; Takigawa N; Fujiwara Y; Tabata M; Tanimoto M
PLoS One; 2009 Nov; 4(11):e7835. PubMed ID: 19915681
[TBL] [Abstract][Full Text] [Related]
4. Pravastatin has no advantage in small-cell lung cancer.
Brower V
Lancet Oncol; 2017 Apr; 18(4):e204. PubMed ID: 28285843
[No Abstract] [Full Text] [Related]
5. Platinum versus non-platinum chemotherapy regimens for small cell lung cancer.
Amarasena IU; Chatterjee S; Walters JA; Wood-Baker R; Fong KM
Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD006849. PubMed ID: 26233609
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcome of amrubicin therapy according to the prior chemotherapy sensitivities of extensive small cell lung cancer.
Mitsuoka S; Kudoh S; Kimura T; Yoshimura N; Tanaka H; Suzumura T; Umekawa K; Nagata M; Ueda T; Hirata K
Osaka City Med J; 2011 Dec; 57(2):59-66. PubMed ID: 22443079
[TBL] [Abstract][Full Text] [Related]
7. Association between incremental gains in the objective response rate and survival improvement in phase III trials of first-line chemotherapy for extensive disease small-cell lung cancer.
Hotta K; Kiura K; Fujiwara Y; Takigawa N; Oze I; Ochi N; Tabata M; Tanimoto M
Ann Oncol; 2009 May; 20(5):829-34. PubMed ID: 19221150
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy: Irinotecan or etoposide as front-line therapy for SCLC?
Johnson FM; Glisson BS
Nat Rev Clin Oncol; 2009 Oct; 6(10):562-3. PubMed ID: 19786998
[No Abstract] [Full Text] [Related]
9. Extensive-stage small-cell lung cancer--moving beyond response rate?
Ferraldeschi R; Lorigan P
Ann Oncol; 2009 May; 20(5):801-2. PubMed ID: 19403933
[No Abstract] [Full Text] [Related]
10. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
[TBL] [Abstract][Full Text] [Related]
11. Platinum versus non-platinum chemotherapy regimens for small cell lung cancer.
Amarasena IU; Walters JA; Wood-Baker R; Fong K
Cochrane Database Syst Rev; 2008 Oct; (4):CD006849. PubMed ID: 18843733
[TBL] [Abstract][Full Text] [Related]
12. Primary Prophylaxis of Febrile Neutropenia With Pegfilgrastim in Small-cell Lung Cancer Patients Receiving Amrubicin as Second-line Therapy.
Sato Y; Iihara H; Kinomura M; Hirose C; Fujii H; Endo J; Yanase K; Kaito D; Sasaki Y; Gomyo T; Sakai C; Iwai M; Tsuboi Y; Ishihara T; Kobayashi R; Ohno Y; Suzuki A
Anticancer Res; 2021 Mar; 41(3):1615-1620. PubMed ID: 33788757
[TBL] [Abstract][Full Text] [Related]
13. Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy.
Hotta K; Fujiwara Y; Matsuo K; Suzuki T; Kiura K; Tabata M; Takigawa N; Ueoka H; Tanimoto M
Cancer; 2007 Mar; 109(5):939-48. PubMed ID: 17285602
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naïve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901.
Morikawa N; Inoue A; Sugawara S; Maemondo M; Harada T; Harada M; Fujita Y; Katoh T; Yokouchi H; Watanabe H; Usui K; Suzuki T; Sakakibara-Konishi J; Nagai H; Kanbe M; Nukiwa T
Lung Cancer; 2017 Sep; 111():38-42. PubMed ID: 28838395
[TBL] [Abstract][Full Text] [Related]
15. Analysis of lung cancer patients enrolled in CTEP (cancer therapy evaluation program)-sponsored phase I trials.
Gadgeel SM; Ivy P; Chen W; Mauer J; Smith D; Lorusso P
Clin Lung Cancer; 2011 Jul; 12(4):218-23. PubMed ID: 21726820
[TBL] [Abstract][Full Text] [Related]
16. Advances in pharmacotherapy of small cell lung cancer.
Kalemkerian GP
Expert Opin Pharmacother; 2014 Nov; 15(16):2385-96. PubMed ID: 25255939
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of amrubicin-based regimen used as first-line for extensive-disease small-cell lung cancer: A meta-analysis of randomized controlled trials.
Liu CQ; Tian D; Wang N; Meng XP; Yang JD; Li HW; Zhao N; Zhao S; Liao F; Cui Y
Asia Pac J Clin Oncol; 2018 Apr; 14(2):e81-e87. PubMed ID: 29071806
[TBL] [Abstract][Full Text] [Related]
18. Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005.
Behera M; Ragin C; Kim S; Pillai RN; Chen Z; Steuer CE; Saba NF; Belani CP; Khuri FR; Ramalingam SS; Owonikoko TK
Cancer; 2016 Jan; 122(1):50-60. PubMed ID: 26441041
[TBL] [Abstract][Full Text] [Related]
19. Topotecan monotherapy for the treatment of relapsed small cell lung cancer in elderly patients: A retrospective analysis.
Imai H; Yamada Y; Minemura H; Sugiyama T; Kotake M; Kaira K; Kanazawa K; Nakamura Y; Kasai T; Shibata Y; Kaburagi T; Minato K;
Thorac Cancer; 2018 Dec; 9(12):1699-1706. PubMed ID: 30281216
[TBL] [Abstract][Full Text] [Related]
20. Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy.
Ragavan M; Das M
Curr Treat Options Oncol; 2020 Jun; 21(8):64. PubMed ID: 32601742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
